Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

16.60USD
20 Apr 2018
Change (% chg)

$-0.05 (-0.30%)
Prev Close
$16.65
Open
$16.70
Day's High
$17.30
Day's Low
$16.55
Volume
101,052
Avg. Vol
118,053
52-wk High
$30.35
52-wk Low
$14.48

Chart for

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.73
Market Cap(Mil.): $784.83
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.03 -- --
ROI: -0.04 14.84 14.38
ROE: -0.10 16.34 16.07

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:

13 Feb 2018

BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37

* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS

07 Feb 2018

BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans

* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian

* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN

01 Feb 2018

BRIEF-Lannett Names Timothy Crew To Board Of Directors

* LANNETT COMPANY INC - ‍ WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN​ Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY

21 Dec 2017

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

01 Dec 2017

BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL

* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®

29 Nov 2017

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

06 Nov 2017

BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​

* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​ Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:

06 Nov 2017

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $92.60 -0.41
Pfizer Limited (PFIZ.NS) Rs2,234.20 +69.30
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,121.90 -14.40

Earnings vs. Estimates